🇺🇸 FDA
Patent

US 7674779

RNAi modulation of MLL-AF4 and uses thereof

granted A61PA61P35/00A61P35/02

Quick answer

US patent 7674779 (RNAi modulation of MLL-AF4 and uses thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Mar 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Mar 09 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P35/00, A61P35/02, A61P43/00